This review presents the current knowledge of the processes of tumorigenesis and progression in early lung adenocarcinoma, with a focus on its clinicopathological characteristics and their associations with driver mutations (EGFR, KRAS, and BRAF). Here, EGFR is linked to lung adenocarcinoma.